Feature | December 12, 2013

FDA Panel Votes Favorably on Boston Scientific's Watchman Transcatheter LAA Occluder

Watchman is first transcatheter left atrial appendage occluder to go before FDA for approval

Watchman, LAA occluder, atrial fibrillation
December 12, 2013 — The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee voted favorably Dec. 11 in a 13-1 vote that the benefits of the Watchman Left Atrial Appendage Closure (LAA) device outweigh the risks. The FDA Panel also voted 13-1 that there is reasonable assurance the device is safe and effective. The FDA will take into account the panel's review in its final decision on approval of the Watchman device. The company expects a decision from the FDA in the first half of 2014.
 
The Watchman is the first transcatheter LAA occluder device to go before the FDA for review. The device is designed to replace warfarin therapy for patients with atrial fibrillation (AF) to prevent blood clots from forming in the LAA. The device is delivered in a cath lab via catheter through a septal wall puncture from the right into the left atrium. The device self expands into the LAA and is anchored by small barbs. It has a fabric covering with facilitates endothelization. 
 
"We are pleased with the outcome of today's panel, which represents an important milestone toward making this innovative technology available to patients with AF at higher risk for stroke who need an alternative to long-term warfarin therapy," said Kenneth Stein, M.D., chief medical officer, cardiac rhythm management, Boston Scientific. "We appreciate the opportunity to present our comprehensive data supporting the Watchman technology and look forward to continuing discussions with the FDA regarding the panel's comments."
 
The vote of the committee followed a review of clinical data from two randomized control trials, PROTECT AF and PREVAIL, as well as from the CAP (Continued Access Protocol) registry. Watchman is the most studied LAA closure device and the only one with long-term clinical data from 2,000 patients and with almost 4,900 patient-years of follow-up in clinical trials. The Watchman device received CE mark in 2005. In the United States, it is an investigational device, limited to investigational use and not available for sale.
 
The LAA is a thin, sack-like appendix arising from the heart and is believed to be the source of a majority of stroke-causing blood clots in people with AF. The most common treatment for stroke prevention in patients with AF is blood-thinning warfarin therapy. Despite its proven efficacy, long-term warfarin therapy is not well tolerated by some patients and carries a significant risk for bleeding complications. Due to the drug’s narrow therapeutic window it also requires regular blood test monitoring. 
 
For more information: www.bostonscientific.com 
 
Bottom of Form
 

Related Content

Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT)| July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
First Patient Treated in U.S. Feasibility Study of LimFlow Critical Limb Ischemia Device
News | Peripheral Arterial Disease (PAD)| July 17, 2017
LimFlow SA announced enrollment of the first patient in the U.S. feasibility study of the LimFlow Percutaneous Deep...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Edwards Sapien 3 TAVR valve will be implanted in asymptomatic aortic stenosis patients in the EARLY TAVR Trial
Feature | Heart Valve Technology| July 14, 2017
July 14, 2017 — Morristown Medical Center, part of Atlantic Health System, has randomized the first patient in the wo
Cardiologs ECG Analysis Platform Receives FDA Clearance
Technology | ECG Monitoring Services| July 13, 2017
Cardiologs Technologies SAS announced that it has received U.S. Food and Drug Administration (FDA) clearance of its...
long-duration dual anti-platelet therapy (L-DAPT) compared to short-duration dual antiplatelet (S-DAPT) after DES stent implantation
News | Antiplatelet and Anticoagulation Therapies| July 12, 2017
June 12, 2017 — Researchers have evaluated the long-term efficacy and safety of long-duration dual anti-platelet ther
iRhythm and Stanford Researchers Develop Deep Learning-Based Cardiac Arrhthymia Detection Algorithm
News | Artificial Intelligence| July 11, 2017
iRhythm Technologies Inc. announced a collaboration with the Stanford Machine Learning Group that has resulted in the...
Medtronic's CoreValve Evolut R gained FDA approval for intermediate risk patients

An illustration of the self-expanding CoreValve Evolut R TAVR valve half deployed in the aortic root.

Feature | Heart Valve Technology| July 10, 2017
The U.S. Food and Drug Administration (FDA) has cleared an additional indication to expand the use Medtronic's self-...
Overlay Init